This is the authors' abstract. We don't add key points for this paper.
To our knowledge, this study is the first randomized phase III study to demonstrate the clinical benefit of anti-PD-L1 antibody in combination with bevacizumab and chemotherapy in patients with EGFR- or ALK-mutated NSCLC who have progressed on relevant targeted therapy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Park et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: